# OnCo record nct05363280 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05363280/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05363280", "NCT05363280" ;
  schema:name "Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment"@en ;
  schema:description "A phase 2 trial of AL8326 40 mg in small-cell lung cancer, renal cell carcinoma and non-small-cell lung cancer, run by Advenchen Pharmaceuticals, LLC., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05363280/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05363280> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2022-11-01" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/nsclc/> ;
  onco:companies <https://onco.cc/companies/advenchen-laboratories/> .